Ras pathway-driven forms of melanoma can be treated with various kinase inhibitors, including the Raf inhibitors vemurafinib and dabrafenib and the MEK inhibitors trametinib and cobimetinib (Luke and Hodi, 2013; Robert et al., 2015). Here, MAP2K7 is linked to melanoma.